-- 
Teva, Delek, Elbit Imaging, Bioline: Israeli Equity Preview

-- B y   G w e n   A c k e r m a n
-- 
2011-09-07T06:38:07Z

-- http://www.bloomberg.com/news/2011-09-07/teva-delek-elbit-imaging-bioline-israeli-equity-preview.html
The following stocks may rise or
fall in Israeli markets. Stock symbols are in parentheses after
the company names and prices are from the last close unless
otherwise stated.  The TA-25 Index lost 2.8 percent to 1,032.74 in  Tel Aviv .  Bioline RX Ltd. (BLRX)  : The biopharmaceutical company
signed a license agreement for the development and
commercialization of its BL-7050 treatment for neuropathic and
inflammatory pain. Bioline dropped 4.9 percent to 1.209 shekels.  Delek Group Ltd. (DLEKG)  :  Israel ’s Antitrust Authority
is considering naming gas companies a monopoly in the supply of
natural gas to the country. Isaac Tshuva’s holding company has
stakes in the country’s two largest gas finds through Delek
Drilling-LP and Avner Oil Exploration-LP. Delek Group declined
7.5 percent to 552.10 shekels. Delek Drilling lost 7.9 percent
to 9.35 shekels. Avner slumped 8 percent to 1.65 shekels.  Elbit Imaging Ltd. (EMIT)  : The holding company that
invests in real estate said its notes were lowered to
ilBBB+/Negative from ilA/Watch Negative at Standard & Poor’s
Maalot. Elbit dropped 3.3 percent to 9.038 shekels.  Teva Pharmaceutical Industries Ltd. (TEVA)  : A trial on a
patent-infringement case over the world’s largest maker of
generic drugs’ multiple-sclerosis treatment Copaxone is expected
to start in  New York . Teva added 1.2 percent to 144.20 shekels.  To contact the reporter on this story:
Gwen Ackerman in Jerusalem at 
 gackerman@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  